Myosin inhibition has the potency to reverse multiple pathophysiological mechanisms in hypertrophic obstructive cardiomyopathy—even in patients with advanced age and with long-standing, resistant, and symptomatic disease. This evidence concerns the gene MYH14 and hypertrophic cardiomyopathy.